恒河猴对包含乙型肝炎病毒S、PreS1和Core抗原的新型疫苗的免疫应答
本研究在恒河猴中评价包含乙型肝炎病毒S、PreS1和Core抗原的两种DNA疫苗、HBV颗粒亚单位疫苗及重组痘病毒疫苗的免疫应答,纵向观察至首次接种后98周。DNA疫苗接种后抗PreS1抗体比抗S或抗Core抗体出现更快;RVJSS1和RVJCS1加强后抗S、PreS1和C的抗体及细胞免疫应答显著增强,其中对C的细胞免疫应答最强且最持久;HBSS1加强可恢复免疫应答,至第74和98周仍可检出,第52周检测到强中和活性。结论认为新型HBV候选疫苗尤其治疗性应用应包含PreS1和Core抗原。
要点
- DNA疫苗接种后恒河猴抗PreS1抗体比抗S或抗Core抗体诱导更快。
- RVJSS1和RVJCS1加强后抗S、PreS1和C的抗体及细胞免疫应答显著增强。
- HBSS1加强可恢复免疫应答,第52周检测到强中和活性。
核心结论
- 新型HBV候选疫苗尤其用于治疗性应用时应包含PreS1和Core抗原。
研究设计与样本
- 在恒河猴中开展纵向研究,评价两种DNA疫苗(pVRC-SS1、pVRC-CS1)、HBV颗粒亚单位疫苗(HBSS1)及重组痘病毒疫苗(RVJSS1、RVJCS1)的体液免疫和细胞介导免疫,观察至首次接种后98周。
主要发现
- 恒河猴DNA疫苗接种后抗PreS1抗体比抗S或抗Core抗体诱导更快。
- RVJSS1和RVJCS1加强的恒河猴针对S、PreS1和C的抗体及细胞介导免疫应答显著增强,其中对C的细胞免疫应答最强且最持久。
- HBSS1加强可恢复针对S、PreS1和C的免疫应答,首次接种后第74周和第98周仍可检出。
- 第52周检测到强中和活性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapeutic vaccines represent a unique approach to hepatitis B virus (HBV) treatment and have the potential to induce long-term control of infection. This study explored the immune responses of rhesus macaques to novel vaccines comprising the S, PreS1, and Core antigens of the HBV that showed promise as prophylactic and therapeutic approaches in a mouse model. The tested vaccines included two DNA vaccines (pVRC-SS1, pVRC-CS1), an HBV particle subunit (HBSS1) vaccine and the recombinant vaccinia virus- (RVJ-) based vaccines (RVJSS1 and RVJCS1) in which SS1 containing S (1-223 aa) and PreS1 (21-47 aa), CS1 containing Core (1-144 aa) and PreS1 (1-42 aa). The humoral immunity and cell-mediated immunity (CMI) induced by vaccines comprising the S, PreS1, and Core antigens of HBV were investigated in a longitudinal study that continued up to 98 weeks after the firstvaccination. In rhesus macaques, anti-PreS1 antibody was induced more rapidly than anti-S or anti-Core antibody after DNA vaccination. The antibody and cell-mediated immune responses against S, PreS1, and C were significantly enhanced in macaques boosted with RVJSS1 and RVJCS1, whereas the cell-mediated response to C was most robust and durable. The immune response to S, PreS1, and C was restored by HBSS1 boosting and detected in macaques until weeks 74 and 98 after the first vaccination. Additionally, robust neutralizing activity was detected at week 52. In conclusion, novel HBV vaccine candidates, especially those used for therapeutic applications should incorporate the PreS1 and Core antigens.
引用
- Chuai X, Xie B, Chen H, et al. The immune response of rhesus macaques to novel vaccines comprising hepatitis B virus S, PreS1, and Core antigens. Vaccine. 2018. PMID: 29778513. doi:10.1016/j.vaccine.2018.05.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。